At the news
? BULLISHIMPACT 5/10 8-K filed Jul 27, 2026 at 07:07 ET
Neumora Therapeutics reported favorable pre-clinical toxicology results for NMRA-215, a brain-penetrant oral NLRP3 inhibitor in development for obesity and cardiometabolic disease. A repeat 13-week rat study found no unexpected adverse findings, clearing a key safety concern and enabling the company to plan an IND submission in Q4 2026 with a Phase 1 study by end of 2026. This removes a significant pipeline risk and supports advancement toward the clinic.
- Repeat 13-week rat toxicology study (162 animals) showed no unexpected in-life adverse findings, resolving concerns from a prior study where 5 of 142 animals had adverse events.
- Company opened a for-cause audit of the prior study, which revealed discrepancies; management believes prior findings were not related to NMRA-215.
- Plans to submit an IND for NMRA-215 in Q4 2026 and initiate a Phase 1 study by the end of 2026.
- NMRA-215 is a potentially best-in-class, highly brain-penetrant, oral NLRP3 inhibitor targeting obesity and cardiometabolic disease with pre-clinical data showing class-leading weight loss and additive effects with semaglutide.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access